Abstract
Hepatocellular carcinoma (HCC) is not sensitive to radiotherapy and chemotherapy and experiences postoperative relapse extremely easy, which is the major cause of the high mortality rate. The Notch signaling pathway is expected to become a new target for the biological treatment of HCC. We searched databases for studies that evaluated the expression of Notch receptors and/or ligands in human HCC tissue. The search yielded 15 studies that enrolled 1643 patients. Compared with non-HCC tissues, Notch 1 was associated with a higher expression level (odds risk 1.59, 95% confidence interval 0.34 to 7.45), as well as Notch 3 (2.63, 0.69 to 10.02), Notch 4 (1.33, 0.74 to 2.38) and Jagged 1 (1.47, 0.23 to 9.53); however, Notch 2 showed the opposite result (0.60, 0.30 to 1.20). Larger tumor size (>5 cm), metastasis positive, and micro vascular invasion positive were features that were associated with over-expression in Notch 1 according to the clinicopathological features. The expression levels of Notch 1, 3, 4 and Jagged 1 were associated with higher expression in HCC tissues, while Notch 2 had the opposite result. This study is registered with PROSPERO (CRD42017055782).
References
Feb 28, 2002·Biochemical and Biophysical Research Communications·Kiyoshi ShimizuHisamaru Hirai
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
Aug 20, 2002·Nature Medicine·Sanne WeijzenLucio Miele
Mar 25, 2004·The American Journal of Pathology·Charlotte Harken JensenHanne Cathrine Bisgaard
Feb 22, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Adrien CroqueloisMarkus H Heim
Apr 26, 2008·BMJ : British Medical Journal·Gordon H GuyattUNKNOWN GRADE Working Group
Jul 23, 2009·Annals of Internal Medicine·David MoherUNKNOWN PRISMA Group
Sep 5, 2009·Neoplasma·M WangL Che
Jul 24, 2010·European Journal of Epidemiology·Andreas Stang
Jan 7, 2011·Journal of Clinical Epidemiology·Howard BalshemGordon H Guyatt
Nov 28, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Liang ZhouKe-Feng Dou
Mar 8, 2013·PloS One·Liang ZhouKefeng Dou
Jun 8, 2013·Hepatobiliary & Pancreatic Diseases International : HBPD INT·Soomin AhnCheol-Keun Park
Aug 29, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Fu-Sheng WangHong-Yang Wang
May 23, 2015·Scientific Reports·Xun YuanKongming Wu
May 29, 2015·Liver Cancer·Masatoshi Kudo
Jun 30, 2015·PloS One·Xun YuanKongming Wu
Aug 8, 2015·Oncology Reports·Yoshihiro HayashiGang-Hong Lee
Sep 6, 2015·Cancer Letters·Xun YuanKongming Wu
Nov 7, 2015·OncoTargets and Therapy·Tao WuHui Guo
Feb 26, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Lei LiXin Chen
Mar 2, 2016·World Journal of Experimental Medicine·Roberto MazzantiRenato Tassi
Apr 15, 2016·Cellular Signalling·Jiesi ZhouYangXin Fu
Apr 20, 2016·Biochimica Et Biophysica Acta·Hui JiaFan Feng
Jan 10, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jiliang QiuYunfei Yuan
Apr 21, 2017·Oncotarget·Bo ZhuWenbo Yu
Apr 30, 2017·Cancer Letters·Zhixin LiuJianguo Wu
May 24, 2017·Oncotarget·Sofia Nascimento Dos SantosEmerson Soares Bernardes
Jul 8, 2017·Scientific Reports·Jing-Ni ZhuLi-Xin Wei
Sep 9, 2017·Oncotarget·Ding CaoJianping Gong
Citations
Mar 22, 2019·Cell Proliferation·Zhiqiang ChenJindao Wu
Oct 31, 2019·Clinical and Experimental Pharmacology & Physiology·Yomna S Mo'menMohamed A Kandeil
Jun 25, 2020·Cells·Gillian MooreTracy Robson
Jul 5, 2018·Cell Death & Disease·Yingshi ZhangQingchun Zhao
Apr 20, 2018·Journal of Cellular Physiology·Keywan Mortezaee
Jan 10, 2019·Cancer Cell International·Libing YuanShoujun Song
Jan 23, 2021·Frontiers in Oncology·Yuehong CuiTianshu Liu
Mar 20, 2021·ACS Nano·Xuan ZhangHuanghao Yang
Jun 17, 2021·BMC Cancer·Fan WuBai-Lin Wang
Jun 13, 2019·ACS Nano·Tingting SunZhigang Xie
Dec 2, 2021·American Journal of Physiology. Gastrointestinal and Liver Physiology·Yurii V StepanovTymish Y Ohulchanskyy